Figure 2: Stable transgene expression and attenuation of artLCMV in vivo. | Nature Communications

Figure 2: Stable transgene expression and attenuation of artLCMV in vivo.

From: Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy

Figure 2

(a–d) Viremia of AGRAG mice infected with r3LCMV-GFP (n=7), artLCMV-GFP (n=7) or LCMVwt (n=3, a,d). Symbols show the mean±s.e.m. N=2. Blood samples obtained on d5 and d120 were processed for NP-IFF and GFP-IFF (b). Bars represent the mean±s.e.m. of seven mice. N=2. Representative NP-IFF and GFP-IFF analyses of d150 serum (c, scale bar, 0.5 cm). Representative liver sections analysed for GFP+ cells on d150 (d, scale bar, 50 μm). (e) Growth kinetics of LCMVwt, r3LCMV-GFP and r2LCMV-Srec#1 on BHK-21 cells (compare Supplementary Fig. 2e). Symbols represent the mean of three replicates (s.e.m. error bars hidden in the symbol size). N=2. Data in a (120 days after infection) and e (48 h after infection) were analysed by one-way ANOVA with Bonferroni post hoc test. Data in b were analysed by unpaired two-tailed Student’s t-test. NS, not significant; **P<0.01 and ***P<0.001.

Back to article page